The iconic rise of Viagra has long been a benchmark of pharmaceutical success, but its future within the broader industry now raises questions about potential returns . Copycat versions are eroding patent protection , prompting worries that betting on companies heavily reliant to Viagra's previous standing could be a speculative move , especially g